Epizyme, Inc.
(NASDAQ : EPZM)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
VTLVital Therapies, Inc.
1.50%13.513.3%$792.68m
AMGNAmgen Inc.
-1.30%203.331.3%$763.42m
GILDGilead Sciences, Inc.
-0.87%63.550.9%$384.95m
CELGCelgene Corporation
0.20%95.411.3%$349.42m
BIIBBiogen Inc.
-1.93%231.171.3%$303.35m
ILMNIllumina, Inc.
-1.01%285.743.5%$300.78m
VRTXVertex Pharmaceuticals Incorporated
-1.49%184.301.9%$263.05m
EXASExact Sciences Corporation
1.31%119.7124.1%$251.26m
ALXNAlexion Pharmaceuticals, Inc.
-0.63%111.972.0%$249.39m
REGNRegeneron Pharmaceuticals, Inc.
-0.87%295.772.6%$215.15m
AAgilent Technologies, Inc.
-0.32%71.521.6%$205.85m
SRPTSarepta Therapeutics, Inc.
-17.39%99.3914.7%$127.10m
INCYIncyte Corporation
-0.30%84.272.5%$99.96m
BMRNBioMarin Pharmaceutical Inc.
-1.67%76.124.3%$93.13m
GHDXGenomic Health, Inc.
-0.14%74.121.8%$90.30m

Company Profile

Epizyme, Inc. is a clinical-stage biopharmaceutical company, which engage in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. It also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA.